结肠直肠癌腹膜转移的腹腔药物治疗研究

doi:10.16139/j.1007-9610.2021.01.007

摘要/Abstract

中图分类号:

程国柱, 蔡国响. 结肠直肠癌腹膜转移的腹腔药物治疗研究[J]. 外科理论与实践, 2021, 26(01): 34-37.

CHENG Guozhu, CAI Guoxiang. Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 34-37.

参考文献 27

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2]	Franko J, Shi Q, Goldman CD, et al. Treatment of co-lorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3):263-267. doi: 10.1200/JCO.2011.37.1039 pmid: 22162570
[3]	Mo S, Cai G. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016:1516259.
[4]	Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis[J]. World J Gastroenterol, 2014, 20(35):12493-12500.
[5]	Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer[J]. J Clin Med, 2018, 7(12):567.
[6]	Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer[J]. Ann Surg Oncol, 2008, 15(9):2426-2432. doi: 10.1245/s10434-008-9966-2 pmid: 18521686
[7]	Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial[J]. Eur J Cancer, 2016, 53:155-162. doi: 10.1016/j.ejca.2015.09.017 pmid: 26751236
[8]	Quenet J, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7[J]. J Clin Oncol, 2018, 36(18 suppl):LBA3503.
[9]	Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO,MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1):44-70. doi: 10.1093/annonc/mdx738 pmid: 29155929
[10]	赵志勋, 裴炜, 熊斌, 等. 结直肠癌腹膜转移诊治中国专家意见(2017)[J]. 中华结直肠疾病电子杂志, 2017, 6(5):360-366.
[11]	Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer[J]. J Surg Oncol, 2020, 121(8):1298-1305.
[12]	Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts[J]. Clin Colorectal Cancer, 2020, 19(4):277-284.
[13]	Qiu C, Li Y, Liang X, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with raltitrexed[J]. Biomed Pharmacother, 2017, 92:149-156.
[14]	Roy P, Canet-Jourdan C, Annereau M, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC[J]. Int J Pharm, 2017, 531(1):143-152.
[15]	Ubink I, Bolhaqueiro ACF, Elias SG, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy[J]. Br J Surg, 2019, 106(10):1404-1414. doi: 10.1002/bjs.11206 pmid: 31197820
[16]	Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase Ⅱ/Ⅲ trial[J]. Int J Cancer, 2010, 127(9):2209-2221.
[17]	Jordan K, Luetkens T, Gog C, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase Ⅱ study-AIO SUP-0108[J]. Eur J Cancer, 2016, 63:127-134. doi: 10.1016/j.ejca.2016.05.004 pmid: 27314448
[18]	Gong Q, Song C, Wang X, et al. Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis[J]. Exp Biol Med (Maywood), 2020, 245(6):542-551.
[19]	Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in co-lorectal peritoneal metastasis: results from the immunoPeCa phase 1 trial[J]. Ann Surg Oncol, 2017, 24(7):1916-1922. doi: 10.1245/s10434-017-5814-6 pmid: 28224367
[20]	Frøysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis[J]. Eur J Surg Oncol, 2021, 47(1):134-138. doi: 10.1016/j.ejso.2019.04.014 pmid: 31036394
[21]	Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressu-rized aerosol as an alternative to liquid solution: first evidence for efficacy[J]. Ann Surg Oncol, 2014, 21(2):553-559.
[22]	Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[23]	Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis[J]. Colorectal Dis, 2016, 18(4):364-371. doi: 10.1111/codi.13130 pmid: 26400556
[24]	Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy(PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. a single center comparative study[J]. Eur J Surg Oncol, 2021, 47(1):139-142.
[25]	Teixeira Farinha H, Grass F, Labgaa I, et al. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy[J]. J Cancer, 2018, 9(1):13-20. doi: 10.7150/jca.21460 pmid: 29290765
[26]	Larbre V, Alyami M, Mercier F, et al. No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis[J]. Anticancer Res, 2018, 38(12):6869-6875.
[27]	Girshally R, Demtroder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1):253. pmid: 27678344

结肠直肠癌腹膜转移的腹腔药物治疗研究

Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[2]	郑亚民, 顾利国, 许臣. 胆囊结石病理生理进展分期和个性化诊治[J]. 外科理论与实践, 2023, 28(02): 94-99.
[3]	李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.
[4]	黄成　胡学庆. 淋巴水肿治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 38-.
[5]	张超, 高雪. 继发进展型多发性硬化的临床诊断进展[J]. 诊断学理论与实践, 2022, 21(06): 669-676.
[6]	殷剑光, 宗雅萍, 沈晓卉, 赵敬坤, 陆爱国. 同时性多原发结肠直肠癌治疗与预后分析（附39例报告）[J]. 外科理论与实践, 2022, 27(06): 540-544.
[7]	许晴, 邵慧英, 陈帅, 全进伟, 周清芬, 王敏慧. 延续健康教育和指导对干预2型糖尿病患者冠状动脉斑块进展的影响[J]. 内科理论与实践, 2022, 17(04): 330-333.
[8]	许梓枫综述, 宗雅萍, 陆爱国审校. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270.
[9]	王凡, 叶俊娜, 杨程德. 回纹型风湿症的诊断与治疗进展[J]. 内科理论与实践, 2022, 17(03): 258-261.
[10]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[11]	樊佳俊许佳李馨韩冬. ３Ｄ打印手指静态进展性牵伸支具的设计及临床应用[J]. 组织工程与重建外科杂志, 2021, 17(4): 308-.
[12]	陈强张世红汤洁莹杨建民李薇薇. Ａ型肉毒毒素治疗化脓性汗腺炎的研究进展 #br#[J]. 组织工程与重建外科杂志, 2021, 17(1): 83-.
[13]	刘诗光, 赵敬坤, 陆爱国, 毛志海. 趋化因子CXCL5和程序性死亡配体 1在结肠直肠癌组织的表达与病人预后的关系[J]. 外科理论与实践, 2021, 26(06): 543-549.
[14]	张华, 陆炜, 杨承翌, 项明洁. 血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[15]	杨盈赤, 宋建宁, 张忠涛. 中国腹腔镜结肠直肠手术的回顾与展望——基于手术病例登记研究和数据库建立的思考[J]. 外科理论与实践, 2021, 26(04): 277-280.